Adial Pharmaceuticals, INC 8-K filings

Adial Pharmaceuticals has entered into a purchase agreement with Alumni Capital LP for up to $5 million in registered shares, with a potential increase to $10 million.

Adial Pharmaceuticals has amended its employment agreement with CEO Cary Claiborne, increasing his bonus target to 50% of his base salary and granting him 350,000 stock options.

Adial Pharmaceuticals has completed a pharmacokinetics study of AD04, showing positive results including dose-proportional exposure and no food effect, which is a key step towards their Phase 3 trial for Alcohol Use Disorder.

Adial Pharmaceuticals' shareholders voted to significantly increase the number of shares available under the company's equity incentive plan, signaling potential for increased stock-based compensation.

Adial Pharmaceuticals has appointed Vinay Shah as its new Chief Financial Officer, effective November 16, 2024, following the resignation of Joseph Truluck.

Adial Pharmaceuticals has entered into a separation agreement with Dr. Bankole Johnson, including a one-time payment, potential consulting services, and milestone-based compensation.

Adial Pharmaceuticals has entered into an agreement with H.C. Wainwright & Co. to sell up to $4.28 million of its common stock through an at-the-market offering.

Adial Pharmaceuticals has terminated its consulting agreement with Dr. Bankole A. Johnson, resulting in his departure as Chief Medical Officer effective May 17, 2024.

Adial Pharmaceuticals has successfully raised $3.5 million by inducing the exercise of existing warrants and issuing new warrants for future stock purchases.

Adial Pharmaceuticals has appointed Tony Goodman as Chief Operating Officer to lead strategic growth initiatives, including clinical development and commercial planning for AD04.

Adial Pharmaceuticals' stockholders approved the issuance of shares upon warrant exercises and an adjournment proposal at a special meeting on January 11, 2024.